Report
Pharma Mar : Zepzelca making good progress
>Good Q4 2021 numbers showed higher sales and royalties from Zepzelca - Early last week Pharma Mar published strong numbers for Q4 2021 thanks to the commercial success of Zepzelca. Total revenues recovered traction growing at +6% y-o-y in Q4 2021 (vs -13% in Q3 2021), 14% above our estimates and 10% above consensus expectations. EBITDA surged 121% y-o-y, well above our estimate and the consensus (€ 45m vs € 8m expected) thanks to the higher contribution from the Othe...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Isabel Carballo
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.